For decades, a prostate cancer diagnosis has often meant choosing between two deeply unpleasant options: aggressive treatment with life-altering side effects, or anxious, watchful waiting. A new NHS study suggests there might finally be a better path.
Researchers followed nearly 3,500 men over ten years as part of a major trial into focal therapy, a more targeted approach that destroys cancerous tissue while leaving healthy parts of the prostate largely intact. The results, published this week, suggest the technique significantly reduces the risk of the debilitating side effects that plague so many men after conventional treatment.
Traditional options like radical surgery or radiotherapy work, but they’re blunt instruments. Urinary incontinence and erectile dysfunction affect a substantial proportion of men who go through them, often permanently. For a cancer that’s frequently slow-growing and caught early, that trade-off has always felt brutally unfair.
Focal therapy, by contrast, uses techniques such as high-intensity focused ultrasound or cryotherapy to target only the tumour. Think of it less like clearing a whole field and more like pulling up a single weed.
Among the men in the trial, rates of incontinence and sexual dysfunction were notably lower than those typically reported after surgery or radiotherapy. Cancer control outcomes, meanwhile, remained encouraging across the ten-year follow-up period, though researchers were careful to note that longer-term data is still needed.
“This is not a treatment for everyone,” one of the lead clinicians involved in the study noted, “but for the right patient, it represents a genuinely different conversation about quality of life.”
That nuance matters. Focal therapy works best for men with localised, intermediate-risk cancer. It’s not a universal solution, and the NHS is still in the process of rolling it out more widely beyond specialist centres.
Around 52,000 men are diagnosed with prostate cancer in the UK every year, making it the most common cancer in men. Anything that can preserve quality of life without compromising survival is worth taking seriously.
The bigger question now is how quickly the NHS can scale this up, and whether funding and training will keep pace with the clinical evidence.
